GSK owns 76.5% of ViiV Healthcare and Pfizer only 13.5%, GSK is definitely the big boss here.
No doubt Pfizer is a big player in the Covid treatment space, we all know the success they have with Paxlovid, alongside Remdesivir (Gilead) and Molnupiravir (Merck) being the only small molecule antivirals recommended by the FDA.
Gilead and GSK are still leaders in the small molecule antivirals space in terms of research and market share, partnering with either makes the most sense for BIT to commercialise BIT225.
A few folks also mentioned about the INTREPID Alliance, who have a keen interest on developing small molecule antivirals, would be interesting to see if BIT225 makes it to the initial list of 25 compounds which is set to announce later this year, it is the perfect candidate in my opinion.
https://www.intrepidalliance.org/who-we-are
Anyway, as we all love to say - not long now.
GLTA
Ann: Results of AGM, page-200
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
-0.003(5.17%) |
Mkt cap ! $49.62M | |||
| Open | High | Low | Value | Volume |
| 5.8¢ | 5.8¢ | 5.4¢ | $41.34K | 730.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5797 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 20140 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.4¢ |
Change
-0.003 ( 6.90 %) |
||||
| Open | High | Low | Volume | ||
| 5.9¢ | 5.9¢ | 5.3¢ | 119512 | ||
| Last updated 15.48pm 10/05/2024 ? | |||||
| BIT (ASX) Chart |